Literature DB >> 16400639

Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study.

Cornelia L Trimble1, James Kauderer, Richard Zaino, Steven Silverberg, Peter C Lim, James J Burke, David Alberts, John Curtin.   

Abstract

BACKGROUND: Adenocarcinoma of the endometrium is the most common gynecologic malignancy in the United States, accounting for approximately 36,000 diagnoses of invasive carcinoma annually. The most common histologic type, endometrioid adenocarcinoma (EC), accounts for 75-80% of patients. The objective of this work was to estimate the prevalence of concurrent carcinoma in women with a biopsy diagnosis of the precursor lesion, atypical endometrial hyperplasia (AEH).
METHODS: This prospective cohort study included women who had a community diagnosis of AEH. Diagnostic biopsy specimens were reviewed independently by three gynecologic pathologists who used International Society of Gynecologic Pathologists/World Health Organization criteria. Study participants underwent hysterectomy within 12 weeks of entry onto protocol without interval treatment. The hysterectomy slides also were reviewed by the study pathologists, and their findings were used in the subsequent analyses.
RESULTS: Between November 1998 and June 2003, 306 women were enrolled on the study. Of these, 17 women were not included in the analysis: Two patients had unreadable slides because of poor processing or insufficient tissue, 2 patients had only slides that were not endometrial, the slides for 5 patients were not available for review, and 8 of the hysterectomy specimens were excluded because they showed evidence of interval intervention, either progestin effect or ablation. In total, 289 patients were included in the current analysis. The study panel review of the AEH biopsy specimens was interpreted as follows: 74 of 289 specimens (25.6%) were diagnosed as less than AEH, 115 of 289 specimens (39.8%) were diagnosed as AEH, and 84 of 289 specimens (29.1%) were diagnosed as endometrial carcinoma. In 5.5% (16 of 289 specimens), there was no consensus on the biopsy diagnosis. The rate of concurrent endometrial carcinoma for analyzed specimens was 42.6% (123 of 289 specimens). Of these, 30.9% (38 of 123 specimens) were myoinvasive, and 10.6% (13 of 123 specimens) involved the outer 50% of the myometrium. Among the women who had hysterectomy specimens with carcinoma, 14 of 74 women (18.9%) had a study panel biopsy consensus diagnosis of less than AEH, 45 of 115 women (39.1%) had a study panel biopsy consensus diagnosis of AEH, and 54 of 84 women (64.3%) had a study panel diagnosis of carcinoma. Among women who had no consensus in their biopsy diagnosis, 10 of 16 women (62.5%) had carcinoma in their hysterectomy specimens.
CONCLUSIONS: The prevalence of endometrial carcinoma in patients who had a community hospital biopsy diagnosis of AEH was high (42.6%). When considering management strategies for women who have a biopsy diagnosis of AEH, clinicians and patients should take into account the considerable rate of concurrent carcinoma. Copyright 2006 American Cancer Society.

Entities:  

Mesh:

Year:  2006        PMID: 16400639     DOI: 10.1002/cncr.21650

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  95 in total

1.  Biomarkers of progestin therapy resistance and endometrial hyperplasia progression.

Authors:  Kristen Upson; Kimberly H Allison; Susan D Reed; Carolyn D Jordan; Katherine M Newton; Elizabeth M Swisher; Jennifer A Doherty; Rochelle L Garcia
Journal:  Am J Obstet Gynecol       Date:  2012-05-16       Impact factor: 8.661

2.  Endometrial cancer.

Authors:  Kimberly K Leslie; Kristina W Thiel; Michael J Goodheart; Koen De Geest; Yichen Jia; Shujie Yang
Journal:  Obstet Gynecol Clin North Am       Date:  2012-06       Impact factor: 2.844

3.  Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices.

Authors:  Henry D Reyes; Matthew J Carlson; Eric J Devor; Yuping Zhang; Kristina W Thiel; Megan I Samuelson; Megan McDonald; Shujie Yang; Jean-Marie Stephan; Erica C Savage; Donghai Dai; Michael J Goodheart; Kimberly K Leslie
Journal:  Gynecol Oncol       Date:  2015-10-30       Impact factor: 5.482

4.  Nodal metastasis risk in endometrioid endometrial cancer.

Authors:  Michael R Milam; James Java; Joan L Walker; Daniel S Metzinger; Lynn P Parker; Robert L Coleman
Journal:  Obstet Gynecol       Date:  2012-02       Impact factor: 7.661

5.  PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia.

Authors:  Kimberly H Allison; Kristen Upson; Susan D Reed; Carolyn D Jordan; Katherine M Newton; Jennifer Doherty; Elizabeth M Swisher; Rochelle L Garcia
Journal:  Int J Gynecol Pathol       Date:  2012-03       Impact factor: 2.762

Review 6.  Clinical applications of levonorgestrel-releasing intrauterine system to gynecologic diseases.

Authors:  Mi-La Kim; Seok Ju Seong
Journal:  Obstet Gynecol Sci       Date:  2013-03-12

Review 7.  Management of endometrial precancers.

Authors:  Cornelia L Trimble; Michael Method; Mario Leitao; Karen Lu; Olga Ioffe; Moss Hampton; Robert Higgins; Richard Zaino; George L Mutter
Journal:  Obstet Gynecol       Date:  2012-11       Impact factor: 7.661

8.  Risk factors for developing endometrial cancer after benign endometrial sampling.

Authors:  Michelle L Torres; Amy L Weaver; Sanjeev Kumar; Stefano Uccella; Abimbola O Famuyide; William A Cliby; Sean C Dowdy; Bobbie S Gostout; Andrea Mariani
Journal:  Obstet Gynecol       Date:  2012-11       Impact factor: 7.661

9.  Effectiveness of progestin-based therapy for morbidly obese women with complex atypical hyperplasia.

Authors:  Marcia A Ciccone; Stephanie A Whitman; Charlotte L Conturie; Niquelle Brown; Christina E Dancz; Begum Özel; Koji Matsuo
Journal:  Arch Gynecol Obstet       Date:  2019-01-31       Impact factor: 2.344

Review 10.  [Precursor lesions of endometrial carcinoma].

Authors:  S F Lax
Journal:  Pathologe       Date:  2019-02       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.